Actively Recruiting
Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
Led by University of California, San Francisco · Updated on 2026-04-29
3000
Participants Needed
1
Research Sites
769 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
U
UCB Pharma
Collaborating Sponsor
AI-Summary
What this Trial Is About
Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.
CONDITIONS
Official Title
Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female 10 years of age or older
- Diagnosis of hidradenitis suppurativa by a dermatologist or experienced practitioner
- Written informed consent (and assent when applicable) obtained from the participant or legal representative
- Ability to comply with the study requirements
You will not qualify if you...
- Inability to give informed consent or no parent/guardian available to provide consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California San Francisco
San Francisco, California, United States, 94115
Actively Recruiting
Research Team
K
Kaelin Chatterley
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here